Gilead Sciences, Inc. (GILD) Position Boosted by Everence Capital Management Inc.

Everence Capital Management Inc. boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,672 shares of the biopharmaceutical company’s stock after buying an additional 2,520 shares during the period. Everence Capital Management Inc.’s holdings in Gilead Sciences were worth $2,404,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in GILD. Seizert Capital Partners LLC grew its position in Gilead Sciences by 4.6% in the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after buying an additional 27,547 shares in the last quarter. Mawer Investment Management Ltd. grew its position in Gilead Sciences by 17.4% in the 1st quarter. Mawer Investment Management Ltd. now owns 566,100 shares of the biopharmaceutical company’s stock valued at $38,450,000 after buying an additional 84,040 shares in the last quarter. Stelac Advisory Services LLC grew its position in Gilead Sciences by 32.1% in the 1st quarter. Stelac Advisory Services LLC now owns 10,531 shares of the biopharmaceutical company’s stock valued at $715,000 after buying an additional 2,558 shares in the last quarter. KBC Group NV boosted its position in shares of Gilead Sciences by 14.4% during the 1st quarter. KBC Group NV now owns 1,292,881 shares of the biopharmaceutical company’s stock valued at $87,812,000 after purchasing an additional 162,841 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of Gilead Sciences by 75.0% during the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company’s stock valued at $173,148,000 after purchasing an additional 1,092,206 shares in the last quarter. Hedge funds and other institutional investors own 75.94% of the company’s stock.

Shares of Gilead Sciences, Inc. (GILD) opened at $71.64 on Tuesday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The company has a market cap of $93,581.12, a PE ratio of 8.16, a price-to-earnings-growth ratio of -1.20 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same period in the prior year, the firm earned $2.75 earnings per share. The business’s quarterly revenue was down 13.2% on a year-over-year basis. equities research analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.90%. The ex-dividend date was Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.69%.

Several research firms have recently weighed in on GILD. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 7th. Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, September 11th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Vetr lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price objective for the company. in a research report on Monday, September 4th. Finally, Morgan Stanley restated an “equal weight” rating and set a $83.00 price objective (up previously from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $85.03.

In other news, insider John C. Martin sold 73,333 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total value of $5,509,508.29. Following the completion of the sale, the insider now directly owns 3,070,099 shares of the company’s stock, valued at $230,656,537.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders have sold 396,666 shares of company stock valued at $29,283,517 over the last ninety days. Insiders own 1.30% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/01/02/gilead-sciences-inc-gild-position-boosted-by-everence-capital-management-inc.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply